Revelation announces Phase 1 study of Gemini met primary safety endpoint

Revelation Biosciences announced safety and biomarker data for its Phase 1 clinical study, RVL-HV02. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified. Additionally, statistically significant dose dependent upregulation of key biomarkers demonstrating the immunostimulatory preconditioning effect of Gemini were observed. The study, which enrolled 40 healthy individuals 18 to 55 years of age, was conducted in Australia and evaluated escalating doses of intravenously administered Gemini.